Skip to main content
Grafa
Health
DarioHealth revenue slips 4% to $5.2 million
Image for illustrative purposes only. Not a real photo.

DarioHealth revenue slips 4% to $5.2 million

Share
  • DarioHealth reported Q2 2026 revenue of $5.2 million, down from $5.4 million a year earlier, while gross margin improved to 62%.
  • Operating expenses fell 21% and net loss narrowed to $7.9 million, while DRIO shares rose about 3.1% to $7.90.
  • DarioHealth reported $13.1 million of contracted and late-stage ARR as it shifts toward higher-margin recurring B2B2C business.

DarioHealth (NASDAQ:DRIO) reported second-quarter 2026 revenue of $5.2 million, down about 4% year over year, while gross margin improved to 61.7%.

Revenue declined from $5.4 million a year earlier and $5.6 million in Q1 as DarioHealth discontinued certain pharmaceutical-related business while expanding recurring B2B2C revenue.

Operating expenses fell 21% to $9.7 million, operating loss narrowed to $6.5 million and net loss improved to $7.9 million from $13.0 million.

Following the announcement, DarioHealth's share price was up about 3.1% at $7.90 in Nasdaq trading.

DarioHealth reported $13.1 million of contracted and late-stage ARR, with more than 80% tied to multi-condition offerings, alongside new health-plan and Fortune 50 wins.

The company raised $22.8 million net through a July financing, taking pro forma cash to $36.8 million as it expands through Solera, Amwell and provider-backed care.

Frequently asked questions